Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma

Ashkan Heshmatzadeh Behzadi, Leila Haghani, Donna L. D'Souza, Siobhan Flanagan, Christopher Jones

Research output: Contribution to journalArticlepeer-review

Abstract

Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are common liver-directed therapies (LDTs) for unresectable HCC. While both deliver intra-arterial treatment directly to the site of the tumor, they differ in mechanisms of action and side effects. Several studies have compared their side effect profile, time to progression, and overall survival data, but often these lack practical considerations when choosing which treatment modality to use. Many factors can impact operator's choice for treatment, and the choice depends on treatment availability, cost, insurance coverage, operator's comfort level, patient-specific factors, tumor location, tumor biology, and disease stage. This review discusses survival data, time to progression data, as well as more practical patient and tumor characteristics for personalized LDT with TACE or TARE.

Original languageEnglish (US)
Pages (from-to)48-55
Number of pages8
JournalSeminars in Interventional Radiology
Volume41
Issue number1
DOIs
StatePublished - Mar 14 2024

Bibliographical note

Publisher Copyright:
© 2024 Thieme Medical Publishers, Inc.. All rights reserved.

Keywords

  • chemoembolization
  • hepatocellular carcinoma
  • interventional radiology
  • liver-directed therapy
  • radioembolization

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this